Limits...
Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies.

Zheng C, Ou W, Shen H, Zhou Z, Wang J - Biomed Res Int (2015)

Bottom Line: Homogeneity was observed among different studies (P = 0.74).The efficacy of combined therapy with breviscapine and mecobalamin was significantly better than that in control group [P < 0.0001 (OR = 5.01, 95% CI: 3.70-6.78)].Available findings suggest that the therapeutic efficacy of breviscapine combining mecobalamin is superior to mecobalamin alone, and this strategy is required to be popularized in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: School of Public Health, Guangzhou Medical University, Guangzhou 510182, China.

ABSTRACT

Objective: A meta-analysis on combined therapy of diabetic peripheral neuropathy (DPN) with breviscapine and mecobalamin was performed to evaluate the efficacy of this therapy.

Methods: Six English databases (Medline, Cochrane Library, PubMed, EMBASE, Web of Science, and CINAHL) and four Chinese databases (China National Knowledge Infrastructure, VIP Journals Database, CBM, and Wanfang database) were searched for studies on the clinical trials in which DPN was treated with breviscapine and mecobalamin, and RevMan 5.1 package was employed for analyzing pooled trials and publication bias.

Results: A total of 17 articles including 1398 DPN patients were identified. Homogeneity was observed among different studies (P = 0.74). The efficacy of combined therapy with breviscapine and mecobalamin was significantly better than that in control group [P < 0.0001 (OR = 5.01, 95% CI: 3.70-6.78)].

Conclusion: Available findings suggest that the therapeutic efficacy of breviscapine combining mecobalamin is superior to mecobalamin alone, and this strategy is required to be popularized in clinical practice.

Show MeSH

Related in: MedlinePlus

Risk of bias across studies assessed using the Cochrane risk of bias tool.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383387&req=5

fig2: Risk of bias across studies assessed using the Cochrane risk of bias tool.

Mentions: Among 17 studies, there were 1398 patients including 718 treated with breviscapine and mecobalamin and 680 treated with mecobalamin alone. In these studies, patients received diet control, excising, and glucose-lowering therapy before interventions. In most of the studies, patients were treated continuously for 2–6 weeks, except for intervals of 2-3 days in 2 studies [32, 40] and an interval of 2 weeks in 1 study [25]. The detailed information of included studies is shown in Table 1. Among 17 studies, randomized grouping was addressed in 1 study [39], random number method was used in 1 study [25], and only randomization was addressed in remaining studies but the specific method for randomization was not described. Of these studies, only 1 was classified as high risk of bias, and the quality of included studies is shown in Figures 2 and 3.


Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies.

Zheng C, Ou W, Shen H, Zhou Z, Wang J - Biomed Res Int (2015)

Risk of bias across studies assessed using the Cochrane risk of bias tool.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383387&req=5

fig2: Risk of bias across studies assessed using the Cochrane risk of bias tool.
Mentions: Among 17 studies, there were 1398 patients including 718 treated with breviscapine and mecobalamin and 680 treated with mecobalamin alone. In these studies, patients received diet control, excising, and glucose-lowering therapy before interventions. In most of the studies, patients were treated continuously for 2–6 weeks, except for intervals of 2-3 days in 2 studies [32, 40] and an interval of 2 weeks in 1 study [25]. The detailed information of included studies is shown in Table 1. Among 17 studies, randomized grouping was addressed in 1 study [39], random number method was used in 1 study [25], and only randomization was addressed in remaining studies but the specific method for randomization was not described. Of these studies, only 1 was classified as high risk of bias, and the quality of included studies is shown in Figures 2 and 3.

Bottom Line: Homogeneity was observed among different studies (P = 0.74).The efficacy of combined therapy with breviscapine and mecobalamin was significantly better than that in control group [P < 0.0001 (OR = 5.01, 95% CI: 3.70-6.78)].Available findings suggest that the therapeutic efficacy of breviscapine combining mecobalamin is superior to mecobalamin alone, and this strategy is required to be popularized in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: School of Public Health, Guangzhou Medical University, Guangzhou 510182, China.

ABSTRACT

Objective: A meta-analysis on combined therapy of diabetic peripheral neuropathy (DPN) with breviscapine and mecobalamin was performed to evaluate the efficacy of this therapy.

Methods: Six English databases (Medline, Cochrane Library, PubMed, EMBASE, Web of Science, and CINAHL) and four Chinese databases (China National Knowledge Infrastructure, VIP Journals Database, CBM, and Wanfang database) were searched for studies on the clinical trials in which DPN was treated with breviscapine and mecobalamin, and RevMan 5.1 package was employed for analyzing pooled trials and publication bias.

Results: A total of 17 articles including 1398 DPN patients were identified. Homogeneity was observed among different studies (P = 0.74). The efficacy of combined therapy with breviscapine and mecobalamin was significantly better than that in control group [P < 0.0001 (OR = 5.01, 95% CI: 3.70-6.78)].

Conclusion: Available findings suggest that the therapeutic efficacy of breviscapine combining mecobalamin is superior to mecobalamin alone, and this strategy is required to be popularized in clinical practice.

Show MeSH
Related in: MedlinePlus